I don't expect to see much love for small-cap speccies just yet,...

I don't expect to see much love for small-cap speccies just yet, but some are starting to look appealing:

GTG. Its NASDAQ counterpart GENE finally had a good night in the US - up 7% +. Doesn't mean I'd buy GTG on the open, I'm lurking a bit lower.

Otherwise, for the biotech speccies, news (or unexplained volume spikes) will be the clue.

AHZ, according to the thread, may have an announcement any time, but I haven't verified the likelihood.

Discl: holding AHZ/AHZOA